MRK Stock - Merck & Co., Inc.
Unlock GoAI Insights for MRK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $64.17B | $60.12B | $59.28B | $48.70B | $41.52B |
| Gross Profit | $48.98B | $43.99B | $41.87B | $35.08B | $27.90B |
| Gross Margin | 76.3% | 73.2% | 70.6% | 72.0% | 67.2% |
| Operating Income | $20.22B | $2.95B | $18.28B | $13.20B | $5.55B |
| Net Income | $17.12B | $365.00M | $14.52B | $13.05B | $7.07B |
| Net Margin | 26.7% | 0.6% | 24.5% | 26.8% | 17.0% |
| EPS | $6.76 | $0.14 | $5.73 | $5.16 | $2.79 |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Visit WebsiteEarnings History & Surprises
MRKEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2026 | Oct 29, 2026 | — | — | — | — |
Q3 2026 | Aug 4, 2026 | — | — | — | — |
Q2 2026 | Apr 30, 2026 | — | — | — | — |
Q1 2026 | Feb 3, 2026 | $2.08 | — | — | — |
Q4 2025 | Oct 30, 2025 | $2.36 | $2.58 | +9.3% | ✓ BEAT |
Q3 2025 | Jul 29, 2025 | $2.03 | $2.13 | +4.9% | ✓ BEAT |
Q2 2025 | Apr 24, 2025 | $2.13 | $2.22 | +4.2% | ✓ BEAT |
Q1 2025 | Feb 4, 2025 | $1.85 | $1.72 | -7.0% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $1.50 | $1.57 | +4.7% | ✓ BEAT |
Q3 2024 | Jul 30, 2024 | $2.15 | $2.28 | +6.0% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $1.88 | $2.07 | +10.1% | ✓ BEAT |
Q1 2024 | Feb 1, 2024 | $-0.09 | $0.03 | +133.3% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $1.95 | $2.13 | +9.2% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $-2.17 | $-2.06 | +5.1% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $1.32 | $1.40 | +6.1% | ✓ BEAT |
Q1 2023 | Feb 2, 2023 | $1.56 | $1.62 | +3.8% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $1.67 | $1.85 | +10.8% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $1.70 | $1.87 | +10.0% | ✓ BEAT |
Q2 2022 | Apr 28, 2022 | $1.83 | $2.14 | +16.9% | ✓ BEAT |
Q1 2022 | Feb 3, 2022 | $1.53 | $1.80 | +17.6% | ✓ BEAT |
Latest News
Frequently Asked Questions about MRK
What is MRK's current stock price?
What is the analyst price target for MRK?
What sector is Merck & Co., Inc. in?
What is MRK's market cap?
Does MRK pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MRK for comparison